Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Methyluracil→

Methyluracil PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
626-48-2
Molecular formula
C5H6N2O2
Molecular weight
126.11 g/mol
Drug class
Pyrimidine derivativetissue-repair and haematopoietic-support agent
Mechanism of action
A pyrimidine derivative proposed to support nucleic-acid synthesis, cellular proliferation and tissue repair. It has been described as a stimulant of leucopoiesis and epithelial regeneration, although clinical evidence and mechanisms are limited.
Indications / reported uses
  • Topical use in selected wound-healing preparations and systemic use for selected haematopoietic or inflammatory conditions in countries where methyluracil is authorised; indications are product- and jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=methyluracil · https://www.ncbi.nlm.nih.gov/mesh/?term=methyluracil · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Pyrimidine derivative; tissue-repair and haematopoietic-support agent

Mechanism of action

A pyrimidine derivative proposed to support nucleic-acid synthesis, cellular proliferation and tissue repair. It has been described as a stimulant of leucopoiesis and epithelial regeneration, although clinical evidence and mechanisms are limited.

General use cases

  • Topical use in selected wound-healing preparations and systemic use for selected haematopoietic or inflammatory conditions in countries where methyluracil is authorised; indications are product- and jurisdiction-specific.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Methyluracil PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Methyluracil Permitted Daily Exposure (PDE) report (the Methyluracil PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Methyluracil Occupational Exposure Limit (OEL) report (the Methyluracil OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.